Naomi Winick
About
Naomi Winick is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Hematology.
According to data from OpenAlex, Naomi Winick has authored 238 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Public Health, Environmental and Occupational Health, 126 papers in Pediatrics, Perinatology and Child Health and 79 papers in Hematology. Recurrent topics in Naomi Winick's work include Acute Lymphoblastic Leukemia research (180 papers), Childhood Cancer Survivors' Quality of Life (120 papers) and Acute Myeloid Leukemia Research (45 papers). Naomi Winick is often cited by papers focused on Acute Lymphoblastic Leukemia research (180 papers), Childhood Cancer Survivors' Quality of Life (120 papers) and Acute Myeloid Leukemia Research (45 papers). Naomi Winick collaborates with scholars based in United States, Canada and Australia. Naomi Winick's co-authors include Meenakshi Devidas, Stephen P. Hunger, William L. Carroll, Bruce M. Camitta, Michael J. Borowitz, Elizabeth A. Raetz, Mignon L. Loh, Paul S. Gaynon, Andrew J. Carroll and Xiaomin Lu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Naomi Winick
232 papers receiving 9.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Naomi Winick United States | 49 | 6.3k | 4.4k | 3.4k | 2.2k | 1.4k | 238 | 9.6k | ||
| Paul S. Gaynon United States | 60 | 8.6k 1.4× | 5.1k 1.2× | 5.1k 1.5× | 2.4k 1.1× | 2.0k 1.4× | 193 | 11.5k | ||
| Kjeld Schmiegelow Denmark | 56 | 7.8k 1.2× | 6.4k 1.4× | 2.7k 0.8× | 2.1k 1.0× | 2.2k 1.5× | 485 | 13.1k | ||
| Sima Jeha United States | 51 | 4.8k 0.8× | 3.1k 0.7× | 3.4k 1.0× | 2.2k 1.0× | 1.5k 1.1× | 221 | 9.1k | ||
| Meenakshi Devidas United States | 59 | 8.0k 1.3× | 5.5k 1.2× | 4.5k 1.3× | 2.8k 1.3× | 1.8k 1.2× | 311 | 12.6k | ||
| John T. Sandlund United States | 60 | 5.8k 0.9× | 4.0k 0.9× | 3.4k 1.0× | 2.3k 1.0× | 1.7k 1.2× | 169 | 10.5k | ||
| Bruce M. Camitta United States | 60 | 6.9k 1.1× | 4.2k 1.0× | 6.8k 2.0× | 2.4k 1.1× | 1.8k 1.3× | 215 | 12.5k | ||
| Peter G. Steinherz United States | 49 | 4.1k 0.6× | 2.2k 0.5× | 3.5k 1.0× | 1.4k 0.6× | 1.8k 1.2× | 168 | 7.4k | ||
| Beverly J. Lange United States | 64 | 4.6k 0.7× | 2.6k 0.6× | 5.0k 1.5× | 2.1k 0.9× | 3.4k 2.3× | 213 | 11.5k | ||
| Marry M. van den Heuvel‐Eibrink Netherlands | 58 | 3.3k 0.5× | 3.9k 0.9× | 2.3k 0.7× | 2.0k 0.9× | 3.9k 2.7× | 444 | 11.1k | ||
| Henrik Hasle Denmark | 53 | 3.0k 0.5× | 1.8k 0.4× | 4.3k 1.3× | 1.4k 0.6× | 3.1k 2.1× | 311 | 9.1k |
Countries citing papers authored by Naomi Winick
Since
Specialization
Citations
This map shows the geographic impact of Naomi Winick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naomi Winick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naomi Winick more than expected).
Fields of papers citing papers by Naomi Winick
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Naomi Winick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naomi Winick. The network helps show where Naomi Winick may publish in the future.
Co-authorship network of co-authors of Naomi Winick
This figure shows the co-authorship network connecting the top 25 collaborators of Naomi Winick. A scholar is included among the top collaborators of Naomi Winick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naomi Winick. Naomi Winick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Woodward, Adam W., et al.. (2025). An Integrated Method to Evaluate the Treatment Efficacy and Immunogenicity of B‐Cell Acute Lymphoblastic Leukemia Therapeutic Enzyme Formulations. Small Methods. 10(3). e2500945–e2500945.
2.
Smith, Caroline, et al.. (2025). Higher Rates of Hypersensitivity Reactions to Calaspargase Compared With Pegaspargase: A Single Center Retrospective Review. Pediatric Blood & Cancer. 72(5). e31640–e31640.
3.
Hibbitts, Emily, Meenakshi Devidas, Moira K. Whitley, et al.. (2023). Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. 70(11). e30634–e30634.
4.
Kairalla, John A., Emily Hibbitts, Meenakshi Devidas, et al.. (2022). Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. JNCI Journal of the National Cancer Institute. 114(8). 1167–1175.
5.
Burke, Michael J., Meenakshi Devidas, Zhiguo Chen, et al.. (2021). Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232. Leukemia. 36(3). 648–655.
6.
Mattano, Leonard A., Meenakshi Devidas, Kelly W. Maloney, et al.. (2021). Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology. 39(14). 1540–1552.
7.
Gupta, Sumit, Cindy Wang, Elizabeth A. Raetz, et al.. (2020). Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 38(17). 1897–1905.
8.
Angiolillo, Anne, Reuven J. Schore, John A. Kairalla, et al.. (2019). Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. Blood. 134(Supplement_1). 824–824.
9.
Wood, Brent L., David Wu, Beryl Crossley, et al.. (2017). Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 131(12). 1350–1359.
10.
Salzer, Wanda L., Michael J. Burke, Meenakshi Devidas, et al.. (2017). Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer. 124(6). 1150–1159.
11.
Zheng, Daniel J., Xiaomin Lu, Reuven J. Schore, et al.. (2017). Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer. 124(3). 571–579.
12.
Larsen, Eric, Meenakshi Devidas, Si Chen, et al.. (2016). Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232. Journal of Clinical Oncology. 34(20). 2380–2388.
13.
Thienprayoon, Rachel, et al.. (2015). Perceptions of the Pediatric Hospice Experience among English- and Spanish-Speaking Families. Journal of Palliative Medicine. 19(1). 30–41.
14.
Mattano, Leonard A., Meenakshi Devidas, Alison M. Friedmann, et al.. (2014). Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331. Blood. 124(21). 793–793.
15.
Wood, Brent L., Stuart S. Winter, Kimberly P. Dunsmore, et al.. (2014). T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434. Blood. 124(21). 1–1.
16.
Ramsey, Laura B., John C. Panetta, Colton Smith, et al.. (2012). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6). 898–904.
17.
Schultz, Kirk R., W. Paul Bowman, Alexander Aledo, et al.. (2009). Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology. 27(31). 5175–5181.
18.
Blanco, Javier G., Mathew J. Edick, Michael L. Hancock, et al.. (2002). Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 12(8). 605–611.
19.
Smith, Angela K., et al.. (1997). Evidence for Negative Feedback of Extracellular Methotrexate on Blasts of Acute Lymphoblastic Leukemia in Vitro. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(6). 1260–1266.
20.
Tubergen, David G., Clinton F. Stewart, Charles B. Pratt, et al.. (1996). Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid Tumors. Journal of Pediatric Hematology/Oncology. 18(4). 352–361.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul S. Gaynon Breakdown of academic impact, for papers by Kjeld Schmiegelow Breakdown of academic impact, for papers by Sima Jeha Breakdown of academic impact, for papers by Meenakshi Devidas Breakdown of academic impact, for papers by John T. Sandlund Breakdown of academic impact, for papers by Bruce M. Camitta Breakdown of academic impact, for papers by Peter G. Steinherz Breakdown of academic impact, for papers by Beverly J. Lange Breakdown of academic impact, for papers by Marry M. van den Heuvel‐Eibrink Breakdown of academic impact, for papers by Henrik Hasle